Ritzel U, Leonhardt U, Stöckmann F, Ramadori G
Department of Medicine, University of Göttingen, Germany.
Am J Gastroenterol. 1995 Apr;90(4):627-31.
Seven patients with metastasized midgut carcinoids were treated with intravenous infusion of dacarbazine [dimethyltriazenoimidazole carboxamide (DTIC)] (650 mg/m2) every 4 wk. After 2 wk, white blood cell counts decreased transiently in three patients. No other DTIC-associated side effects occurred. Biochemical markers of disease activity decreased significantly in four patients for 4-20 months (mean duration, 12 months). Size of hepatic metastases was reduced or remained unchanged in six patients for 6-20 months (mean duration, 10 months). Clinical symptoms such as cutaneous flush, diarrhea, abdominal pain, constipation, night sweat, or weight loss improved in six of seven patients. We conclude that DTIC represents a useful therapeutic option in the treatment of advanced and metastasized carcinoid tumors.
7例转移性中肠类癌患者接受静脉输注达卡巴嗪[二甲基三氮烯咪唑甲酰胺（DTIC）]（650mg/m²）治疗，每4周1次。2周后，3例患者白细胞计数短暂下降。未出现其他与DTIC相关的副作用。4例患者疾病活动的生化标志物在4至20个月（平均持续时间12个月）内显著下降。6例患者肝转移灶大小在6至20个月（平均持续时间10个月）内缩小或保持不变。7例患者中有6例的皮肤潮红、腹泻、腹痛、便秘、盗汗或体重减轻等临床症状有所改善。我们得出结论，DTIC是治疗晚期和转移性类癌肿瘤的一种有效治疗选择。
